Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI Research Applications: Fewer Than Expected, Geographically Limited

Executive Summary

The Patient-Centered Outcomes Research Institute will look for more ways to engage the research community, particularly in Midwestern states, as the number of applications for research grants has fallen short of expectations.

You may also be interested in...



Inflammatory Bowel Drugs To Go Head-To-Head With PCORI Funding

A number of drug-related comparative effectiveness research projects are approved for PCORI-sponsored research in its second funding cycle. Health IT-related projects also get attention as the institute spends more than $88 million on 51 projects.

PCORI Grant Process Begins, But Challenge Of Involving Nontraditional Researchers Remains

The Patient-Centered Outcomes Research Institute approved its priorities and research agenda May 21, and revealed funding amounts for clinical comparative research the following day. But, as the board of governors’ discussion showed, one of PCORI’s biggest challenges remains how to bring in nontraditional researchers to help give its research a uniquely patient-centered focus.

Slow Pace Of Commenting On National Priorities And Research Agenda Concerns PCORI Board

As of March 1, the Patient-Centered Outcomes Research Institute has received 101 comments on its national priorities and research agenda. Despite expectation of more comments arriving at the March 15 deadline, board members expressed concern on whether enough stakeholders were reached.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel